Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
The main goal of the research study is to determine whether treating renal cell cancer
patients with the study drug, hydroxychloroquine, along with IL-2, a standard treatment of
kidney cancer that has spread to other parts of the body, can make the cancer easier to kill
and eliminate. Another goal is to see how the study drug affects the body's immune cells
which fight cancer cells.